Abu Dhabi: The Higher Committee for Medicine Pricing and Registration approved the registration of 62 new medicines and deferred registration of 28 new medicinal products in its last meeting in Abu Dhabi. It also rejected four others.
The meeting, headed by Dr Ameen Al Amiri, Executive Director for Medical Practices and Licence, Vice-Chairman of the Committee, was attended by members from the Ministry of Health, Abu Dhabi Health Authority and Dubai Health Authority. The members discussed the evaluation of medicines through its sub-technical committees and representatives from various universities and local authorities.
Dr Al Amiri explained that of the medicinal products approved, 23 will enter the region for the first time. Among the newly registered products, 22 are manufactured biological products, three medicines produced by local pharmaceutical factories, and 14 products of branded generics.
The committee also approved the pricing of 61 medicinal products and the registration of manufacturing international sites.
Dr Al Amiri emphasised that the Higher Committee for Medicine Registration depends on general guidelines and regulations when assessing and pricing human medicines.
